REG - Haleon PLC - Haleon 2025 Q3 Trading Statement

HALEONAnnouncement

Yesterday 07:00

For best results when printing this announcement, please click on link below:
https://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20251030:nRSd4049Fa&default-theme=true

RNS Number : 4049F  Haleon PLC  30 October 2025

 

Haleon plc: 2025 Q3 Trading Statement

 

30 October 2025: Haleon plc (the "Company" or "Haleon") today announces its Q3
trading statement for the year ending 31 December 2025 is available at:
http://www.rns-pdf.londonstockexchange.com/rns/4049F_1-2025-10-29.pdf
(http://www.rns-pdf.londonstockexchange.com/rns/4049F_1-2025-10-29.pdf) .

The Q3 trading statement will also be available on the Haleon website
www.haleon.com/investors (http://www.haleon.com/investors) , and has been
submitted in full unedited text to the Financial Conduct Authority's National
Storage Mechanism and will shortly be available for inspection at
https://data.fca.org.uk/#/nsm/nationalstoragemechanism
(https://data.fca.org.uk/#/nsm/nationalstoragemechanism) .

Presentation for analysts and shareholders

A short presentation followed by Q&A will be hosted by Dawn Allen, Chief
Financial Officer at 9:00am GMT (10:00am CET) on 30 October 2025, which can be
accessed at www.haleon.com/investors (http://www.haleon.com/investors) .
 

 

For analysts and shareholders wishing to ask questions on the Q&A call,
please use the dial-in details below which will have a Q&A facility:

 

 UK:         +44 (0) 808 189 0158
 US:         +1 855 979 6654
 All other:  +44 (0) 203 936 2999
 Passcode:   407228

An archived webcast of the Q&A call will be available later on the day of
the results and can be accessed at www.haleon.com/investors
(http://www.haleon.com/investors) .

Amanda Mellor

Company Secretary

 

Enquiries

 

 Investors                                                                         Media

 Jo Russell                               +44 7787 392441                          Zoë Bird                              +44 7736 746167
 Rakesh Patel                             +44 7552 484646                          Victoria Durman                       +44 7894 505730

 Email: investor-relations@haleon.com (mailto:investor-relations@haleon.com)       Email: corporate.media@haleon.com (mailto:corporate.media@haleon.com)

 

About Haleon

Haleon (LSE/NYSE: HLN) is a global leader in consumer health, with a purpose
to deliver better everyday health with humanity. Haleon's product portfolio
spans six major categories - Oral Health, Vitamins, Minerals and Supplements
(VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin
Health and Other. Its long-standing brands - such as Advil, Centrum, Otrivin,
Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are built on
trusted science, innovation and deep human understanding.

 

For more information please visit www.haleon.com (http://www.haleon.com) .

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  TSTFEAFAUEISEIS



            Copyright 2019 Regulatory News Service, all rights reserved